SCHEMBL17549349

SCHEMBL17549349

CCC(=O)Nc1ccc(-c2csc(NC(=O)c3ccco3)n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 10/20 0.71
▸ POLB P06746 4/20 0.71
▸ NPC1 O15118 9/20 0.70
▸ MEN1 O00255 8/20 0.69
▸ KMT2A Q03164 8/20 0.69
▸ MAPT P10636 7/20 0.69
▸ CLK1 P49759 2/20 0.69
▸ MCL1 Q07820 1/20 0.69
▸ HSD17B10 Q99714 1/20 0.69
▸ SMN1; SMN2 Q16637 6/20 0.67
▸ ALDH1A1 P00352 5/20 0.67
▸ MAPK1 P28482 3/20 0.67
▸ LMNA P02545 3/20 0.67
▸ HTT P42858 3/20 0.67
▸ TP53 P04637 2/20 0.67
▸ CASP3 P42574 1/20 0.67
▸ SENP8 Q96LD8 1/20 0.67
▸ SENP7 Q9BQF6 1/20 0.67
▸ SENP6 Q9GZR1 1/20 0.67
▸ PAX8 Q06710 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17107189 0.83 RAB9A (1.00) RAB9APOLBNPC1MEN1KMT2A
SCHEMBL17551125 0.82 RAB9A (0.80) RAB9APOLBNPC1MEN1KMT2A
SCHEMBL17549350 0.78 SMN1; SMN2 (0.60) RAB9APOLBNPC1MEN1KMT2A
SCHEMBL28594556 0.76 CSNK2A1 (0.67) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL93095 0.76 ALDH1A1 (0.75) RAB9APOLBNPC1MEN1KMT2A
SCHEMBL17551124 0.76 MAPT (0.73) RAB9APOLBNPC1MEN1KMT2A
SCHEMBL28583306 0.75 NPC1 (0.69) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL8402291 0.75 MAPT (0.73) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL17549351 0.75 MEN1 (0.62) RAB9APOLBNPC1MEN1KMT2A
SCHEMBL17551132 0.75 KLK7 (1.00) RAB9APOLBNPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951055-B2 Thiazole-based inhibitors of scavenger receptor BI MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-04-24 — — US disclosed
US-9951055-B2 Thiazole-based inhibitors of scavenger receptor BI MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-04-24 — — US disclosed
US-20160060254-A1 THIAZOLE-BASED INHIBITORS OF SCAVENGER RECEPTOR BI THE BROAD INSTITUTE, INC. 2016-03-03 — — US disclosed
US-20160060254-A1 THIAZOLE-BASED INHIBITORS OF SCAVENGER RECEPTOR BI THE BROAD INSTITUTE, INC. 2016-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060254-A1 THIAZOLE-BASED INHIBITORS OF SCAVENGER RECEPTOR BI SCARB1, HAVCR2, LDLR RAB9A 2900/4885POLB 2738/4885NPC1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback